Trileptal, Oxcarbazepine

Trileptal, Oxcarbazepine Newswire

Comprehensive Real-Time News Feed for Trileptal, Oxcarbazepine (generic).

Results 1 - 20 of 33 in Trileptal, Oxcarbazepine (generic)

  1. Court Report - April 2015 #2Read the original story w/Photo

    Monday Apr 13 | JD Supra

    Supernus Pharmaceuticals, Inc. v. Actavis Inc. et al. 1:15-cv-02499; filed April 7, 2015 in the District Court of New Jersey Infringement of U.S. Patent No.

    Comment?

  2. Supernus Pharmaceuticals Announces Issuance Of Sixth U.S. Patent Protecting Trokendi XRRead the original story

    Thursday Apr 2 | BioSpace

    Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on March 31, 2015 of a sixth patent by the United States Patent and Trademark Office covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent provides protection for the product with expiration that is no earlier than 2027.

    Comment?

  3. Supernus Pharmaceuticals' (SUPN) CEO Jack Khattar on Q4 2014 Results - Earnings Call TranscriptRead the original story w/Photo

    Mar 11, 2015 | Seeking Alpha

    Good day, ladies and gentlemen and welcome to Supernus Pharmaceutical Fourth Quarter and Full Year 2014 Earnings Conference Call. At this time all participants are in a listen-only mode.

    Comment?

  4. Supernus: A Specialty Pharma With Significant Growth PotentialRead the original story w/Photo

    Feb 24, 2015 | Seeking Alpha

    Supernus has launched two products in 2013 and the early commercialization efforts are bearing fruit as prescriptions and revenue grew significantly in the last three quarters. Supernus' share price failed to reach the desired levels in the recent two years despite the successful launch of two products in 2013.

    Comment?

  5. Supernus Pharmaceuticals To Present At March Cowen and Company ConferenceRead the original story

    Feb 18, 2015 | BioSpace

    Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview of the Company and host investor meetings at the Cowen and Company Healthcare Conference. A live webcast of the presentation can be accessed by visiting "Events & Presentations" in the Investors section on the Company's website at www.supernus.com .

    Comment?

  6. Supernus to Present at March Cowen ConferenceRead the original story w/Photo

    Feb 18, 2015 | GlobeNewswire

    Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview of the Company and host investor meetings at the Cowen and Company Healthcare Conference. A live webcast of the presentation can be accessed by visiting "Events & Presentations" in the Investors section on the Company's website at www.supernus.com .

    Comment?

  7. Supernus Pharmaceuticals To Host Fourth Quarter And Full Year 2014 Earnings Conference CallRead the original story

    Feb 17, 2015 | BioSpace

    Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company expects to report the financial results for the fourth quarter and full year 2014 after 5:00 PM ET on Tuesday, March 10, 2015. Jack Khattar, President and Chief Executive Officer and Greg Patrick, Chief Financial Officer, will host a conference call to present the fourth quarter and full year results on Wednesday, March 11, 2015 at 9:00 AM ET.

    Comment?

  8. Supernus Pharmaceuticals Sues TWi Pharmaceuticals, Inc. For...Read the original story

    Jan 21, 2015 | BioSpace

    Supernus Pharmaceuticals, Inc. announced that it sued generic drug makers TWi Pharmaceuticals, Inc. and TWi International LLC for infringement of four patents covering its antiepileptic drug Oxtellar XRA . Supernus' United States Patents Nos.

    Comment?

  9. Supernus Pharmaceuticals Sues Par For Infringement Of Trokendi XR PatentsRead the original story

    Jan 18, 2015 | BioSpace

    Supernus Pharmaceuticals, Inc. announced that it sued generic drug makers Par Pharmaceutical Companies, Inc. and Par Pharmaceutical, Inc. for infringement of four patents covering its antiepileptic drug Trokendi XRA . Supernus' United States Patents Nos.

    Comment?

  10. Glenmark Generics Limited - Strategic SWOT Analysis Review - New Study ReleasedRead the original story

    Jan 17, 2015 | PR-inside.com

    Glenmark Generics Limited is a pharmaceutical company. The company develops, manufactures, markets and distributes generic finished dosage forms and active pharmaceutical ingredients.

    Comment?

  11. Supernus Sues Par for Infringement of Trokendi XR(R) PatentsRead the original story w/Photo

    Jan 16, 2015 | GlobeNewswire

    Supernus Pharmaceuticals, Inc. announced that it sued generic drug makers Par Pharmaceutical Companies, Inc. and Par Pharmaceutical, Inc. for infringement of four patents covering its antiepileptic drug Trokendi XR . Supernus' United States Patents Nos.

    Comment?

  12. Supernus Pharmaceuticals Announces Paragraph IV Anda Filing for Oxtellar XRRead the original story

    Dec 9, 2014 | BioSpace

    Supernus Pharmaceuticals, Inc. today announced that on December 9, 2014 the Company received a Paragraph IV Notice Letter from TWi Pharmaceuticals, Inc. advising Supernus of the filing by TWi of an Abbreviated New Drug Application seeking approval for oxcarbazepine extended-release tablets. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Oxtellar XR.

    Comment?

  13. Supernus Announces Paragraph IV Anda Filing for Oxtellar XRRead the original story w/Photo

    Dec 10, 2014 | GlobeNewswire

    Supernus Pharmaceuticals, Inc. today announced that on December 9, 2014 the Company received a Paragraph IV Notice Letter from TWi Pharmaceuticals, Inc. advising Supernus of the filing by TWi of an Abbreviated New Drug Application seeking approval for oxcarbazepine extended-release tablets. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Oxtellar XR.

    Comment?

  14. Sunovion Pharmaceuticals Inc. Submits Supplemental New Drug...Read the original story

    Dec 4, 2014 | BioSpace

    Sunovion Pharmaceuticals Inc. today announced that it has submitted a supplemental new drug application to the U.S. Food and Drug Administration seeking approval for the use of AptiomA as monotherapy treatment of partial-onset seizures. "Sunovion has a deep commitment to helping address the unmet medical needs of people living with partial-onset seizures," said Fred Grossman, Senior Vice President, Clinical Development and Medical Affairs for Sunovion.

    Comment?

  15. Misunderstood Medicine: 'I feel like a normal boy'Read the original story w/Photo

    Nov 24, 2014 | KBCI CBS 2

    A week after his eighth birthday, Forrest Smelser was diagnosed with epilepsy. On bad days he would seize every 15 minutes.

    Comment?

  16. Supernus Pharmaceuticals Sues Zydus Pharmaceuticals (USA) Inc. For...Read the original story

    Nov 23, 2014 | BioSpace

    Supernus Pharmaceuticals, Inc. announced that it sued generic drug makers Zydus Pharmaceuticals Inc. and Cadila Healthcare Limited for infringement of three patents covering its antiepileptic drug Trokendi XRA . Supernus' United States Patents Nos.

    Comment?

  17. Supernus Pharmaceuticals Announces Issuance Of Fifth U.S. Patent Protecting Trokendi XRRead the original story

    Nov 23, 2014 | BioSpace

    Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance of a fifth patent by the United States Patent and Trademark Office covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent provides protection for the product with expiration that is no earlier than 2027.

    Comment?

  18. Supernus Announces Issuance of Fifth U.S. Patent Protecting Trokendi XRRead the original story w/Photo

    Nov 24, 2014 | GlobeNewswire

    Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance of a fifth patent by the United States Patent and Trademark Office covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent provides protection for the product with expiration that is no earlier than 2027.

    Comment?

  19. Misunderstood Medicine: 'I feel like a normal boy'Read the original story w/Photo

    Nov 23, 2014 | KOMO News

    A week after his eighth birthday, Forrest Smelser was diagnosed with epilepsy. On bad days he would seize every 15 minutes.

    Comment?

  20. Supernus Sues Zydus for Infringement of Trokendi XR(R) PatentsRead the original story w/Photo

    Nov 21, 2014 | GlobeNewswire

    Supernus Pharmaceuticals, Inc. announced that it sued generic drug makers Zydus Pharmaceuticals Inc. and Cadila Healthcare Limited for infringement of three patents covering its antiepileptic drug Trokendi XR . Supernus' United States Patents Nos.

    Comment?